|
|
||||||||
Article |
Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois
Correspondence: Dr. George L. Bakris, University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 1027, Chicago, IL 60637. Phone: 773-702-7936; Fax: 773-834-0486; E-mail: gbakris{at}earthlink.net
Blood pressure control reduces decline of kidney function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer renoprotection to a small extent beyond that attributable to blood pressure lowering. These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits.
This article has been cited by other articles:
![]() |
J. R. Ingelfinger Blood-Pressure Control and Delay in Progression of Kidney Disease in Children N. Engl. J. Med., October 22, 2009; 361(17): 1701 - 1703. [Full Text] [PDF] |
||||
![]() |
L. F. Quintana, J. M. Campistol, M. P. Alcolea, E. Banon-Maneus, A. Sol-Gonzalez, and P. R. Cutillas Application of Label-free Quantitative Peptidomics for the Identification of Urinary Biomarkers of Kidney Chronic Allograft Dysfunction Mol. Cell. Proteomics, July 1, 2009; 8(7): 1658 - 1673. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ku, J. Park, J. Vidhun, and V. Campese The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease Arch Intern Med, June 8, 2009; 169(11): 1015 - 1018. [Full Text] [PDF] |
||||
![]() |
A. M. O'Hare, J. S. Kaufman, K. E. Covinsky, C. S. Landefeld, L. V. McFarland, and E. B. Larson Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults? Ann Intern Med, May 19, 2009; 150(10): 717 - 724. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |